Pubblicazioni

IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) Study

2021 - CLINICAL LYMPHOMA MYELOMA & LEUKEMIA

Lawless, S; Sbianchi, G; Morris, C; Iacobelli, S; Bosman, P; Blaise, D; Remenyi, P; Byrne, Jl; Mayer, J; Apperley, J; Lund, J; Kobbe, G; Schaap, N; Isaksson, C; Lenhoff, S; Basak, G; Touzeau, C; Wilson, Kmo; Muniz, Sg; Scheid, C; Browne, P; Anagnostopoulos, A; Rambaldi, A; Jantunen, E; Kroger, N; Schonland, S; Yakoub-Agha, I; Garderet, L

Low-dose clofarabine in combination with a standard remission induction in patients aged 18-60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: Combined phase I/II results of the EORTC/GIMEMA AML-14A trial

2017 - HAEMATOLOGICA

Selleslag, Dominik; Suciu, Stefan; Meloni, Giovanna; Muus, Petra; Halkes, Constantijn J. M.; Venditti, Adriano; Ramadan, Safaa M.; Pruijt, Hans; Meert, Liv; Vignetti, Marco; Marie, Jean-Pierre; Wittnebel, SÃ©bastian; de Witte, Theo; Amadori, Sergio; Willemze, Roelof; Baron, FrÃ©dÃ©ric